HIV – Page 2 – media

ViiV Healthcare gains CHMP Positive Opinion for Juluca (dolutegravir/rilpivirine) in Europe

ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a Positive Opinion recommending marketing authorisation for Juluca (dolutegravir/rilpivirine) for the treatment of HIV infection in adults
- Source: Viivhealthcare
- 456
- March 28, 2018
HIV Juluca New Approvals
HIV linked to higher risks for obesity, cardiovascular disease

HIV infection is associated with a greater risk for abdominal obesity and, perhaps indirectly, a greater risk for elevated LDL cholesterol and hypertriglyceridemia, according to recent findings.
- Source: healio
- 533
- March 13, 2018
cardiovascular disease HIV obesity Researches
FDA approves new HIV treatment for patients who have limited treatment options

Today, the U.S. Food and Drug Administration approved Trogarzo (ibalizumab-uiyk), a new type of antiretroviral medication for adult patients living with HIV who have tried multiple HIV medications in the past (heavily treatment-experienced) and whose HIV infections cannot be successfully treated with other currently available therapies (multidrug resistant HIV, or MDR HIV). Trogarzo is administered intravenously once every 14 days by a trained medical professional and used in combination with other antiretroviral medications.
- Source: Prnewswire
- 484
- March 8, 2018
antiretroviral HIV New Approvals
ViiV kicks off PhIII trial of two-drug HIV regimen

ViiV Healthcare, an HIV specialist firm majority owned by GlaxoSmithKline, has announced the launch of a late-stage study investigating the effectiveness of a two-drug regimen programme in patients with HIV.
- Source: pharmatimes
- 570
- February 12, 2018
Clinical Trial HIV Phase TANGO
Roche introduces new sample collection device for HIV plasma viral load testing

The new card solution helps to simplify blood collection and sample transportation through providing a small amount of a patient’s blood from a fingertip.
- Source: MDBR
- 506
- January 9, 2018
Company Insight HIV Roche
J&J-led coalition launches a landmark efficacy study for an HIV mosaic vaccine

For decades now, investigators have been drawn to HIV vaccine research — a Holy Grail in anti-viral research that would have an enormous impact in a world that still sees two million new infections every year.
- Source: Endpts;
- 519
- December 4, 2017
HIV Market Views vaccine virus
Combination HIV prevention reduces new infections by 42 percent in Ugandan district

A study published today in the New England Journal of Medicine provides real-world evidence that implementing a combination of proven HIV prevention measures across communities can substantially reduce new HIV infections in a population.
- Source: medicalxpress
- 509
- November 30, 2017
ART HIV NIH Researches
FDA approves first two-drug regimen for certain patients with HIV

The U.S. Food and Drug Administration(FDA) today approved Juluca, the first complete treatment regimen containing only two drugs to treat certain adults with human immunodeficiency virus type 1 (HIV-1) instead of three or more drugs included in standard HIV treatment.
- Source: finance.yahoo
- 475
- November 22, 2017
FDA HIV immunodeficiency Juluca New Approvals
UNAIDS announces nearly 21 million people living with HIV now on treatment

Remarkable progress is being made on HIV treatment. Ahead of World AIDS Day, UNAIDS has launched a new report showing that access to treatment has risen significantly. In 2000, just 685 000 people living with HIV had access to antiretroviral therapy. By June 2017, around 20.9 million people had access to the life-saving medicines. Such a dramatic scale-up could not have happened without the courage and determination of people living with HIV demanding and claiming their rights, backed up by steady, strong leadership and financial commitment.
- Source: reliefweb
- 446
- November 21, 2017
antiretroviral HIV UNAIDS
New tool developed to study stem cell transplants as a potential way to treat HIV

A decade ago, the medical world was shocked when a patient in Berlin, Germany, had been declared free of HIV after receiving a stem cell transplant to treat cancer. Doctors have repeatedly tried to replicate the result, but this HIV cure has evaded other patients so far.
- Source: sciencedaily
- 494
- November 14, 2017
HIV Market Views stem cells

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.